Advertisement

Topics

ARCA Biopharma Announces Completion of Enrolment for GENETIC-AF Phase 2B Clinical Trial Evaluating Gencaro (bucindolol hydrochloride)

01:08 EDT 16 Aug 2017 | Drugs.com

WESTMINSTER, Colo., Aug. 16, 2017 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced...

Original Article: ARCA Biopharma Announces Completion of Enrolment for GENETIC-AF Phase 2B Clinical Trial Evaluating Gencaro (bucindolol hydrochloride)

NEXT ARTICLE

More From BioPortfolio on "ARCA Biopharma Announces Completion of Enrolment for GENETIC-AF Phase 2B Clinical Trial Evaluating Gencaro (bucindolol hydrochloride)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...